ES2201296T3 - Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores. - Google Patents

Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores.

Info

Publication number
ES2201296T3
ES2201296T3 ES97921396T ES97921396T ES2201296T3 ES 2201296 T3 ES2201296 T3 ES 2201296T3 ES 97921396 T ES97921396 T ES 97921396T ES 97921396 T ES97921396 T ES 97921396T ES 2201296 T3 ES2201296 T3 ES 2201296T3
Authority
ES
Spain
Prior art keywords
tumor
squalamine
squalemine
treatment
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97921396T
Other languages
English (en)
Spanish (es)
Inventor
Michael Zasloff
Jon Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genaera Corp
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaera Corp filed Critical Genaera Corp
Application granted granted Critical
Publication of ES2201296T3 publication Critical patent/ES2201296T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES97921396T 1996-04-26 1997-04-25 Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores. Expired - Lifetime ES2201296T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1638796P 1996-04-26 1996-04-26
US16387P 1996-04-26

Publications (1)

Publication Number Publication Date
ES2201296T3 true ES2201296T3 (es) 2004-03-16

Family

ID=21776862

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97921396T Expired - Lifetime ES2201296T3 (es) 1996-04-26 1997-04-25 Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores.

Country Status (11)

Country Link
US (1) US6147060A (2)
EP (1) EP0910382B1 (2)
JP (1) JP2000510460A (2)
AT (1) ATE242635T1 (2)
AU (1) AU735884B2 (2)
CA (1) CA2252584C (2)
DE (1) DE69722793T2 (2)
DK (1) DK0910382T3 (2)
ES (1) ES2201296T3 (2)
PT (1) PT910382E (2)
WO (1) WO1997040835A1 (2)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
WO2000009137A2 (en) * 1998-08-12 2000-02-24 Magainin Pharmaceuticals, Inc. Aminosterol compounds and uses thereof
EP1119361A4 (en) * 1998-09-10 2006-10-04 Magainin Pharma TREATMENT OF CARCINOMA WITH SQUALAMINE IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS
HU229520B1 (en) * 1999-02-12 2014-01-28 Scripps Research Inst Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US7820718B1 (en) 1999-04-07 2010-10-26 Roger Williams Hospital Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
ES2344831T3 (es) 2000-06-23 2010-09-08 Mitsubishi Tanabe Pharma Corporation Potenciadores de un efecto antitumoral.
US20020073441A1 (en) 2000-12-13 2002-06-13 Ross Brian D. Compositions and methods for detecting proteolytic activity
JP2005502653A (ja) * 2001-08-20 2005-01-27 トランセーヴ・インコーポレーテッド 肺ガンの治療方法
CA2457148A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
WO2003075889A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
JP2006502233A (ja) * 2002-08-02 2006-01-19 トランセーブ，インク． 白金凝集物およびその製造方法
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
EP1581236B1 (en) * 2002-10-29 2013-10-16 Insmed Incorporated Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US20080194019A1 (en) * 2003-09-09 2008-08-14 Beth Israel Deaconess Medical Center, Inc. Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
JP2007526322A (ja) * 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
WO2005089448A2 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
CN101001633A (zh) * 2004-05-21 2007-07-18 特兰萨夫公司 肺病和肺病前期病症的治疗
JP2008514726A (ja) * 2004-09-30 2008-05-08 ザ ユニヴァーシティー オヴ シカゴ ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法
US20060246124A1 (en) * 2004-11-08 2006-11-02 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally
WO2006099445A2 (en) * 2005-03-14 2006-09-21 Massachusetts Institute Of Technology Nanocells for diagnosis and treatment of diseases and disorders
ES2732251T3 (es) 2005-04-25 2019-11-21 Enterin Inc Dilactato de escualamina cristalino
WO2006119211A2 (en) * 2005-05-02 2006-11-09 Genaera Corporation Methods and compositions for treating ocular disorders
US20060283742A1 (en) * 2005-06-16 2006-12-21 Canel Lightning Co. Ltd. Multi-lamp display packaging for lamps with collapsible lampshades
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056263A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US20070190181A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
US20070122350A1 (en) * 2005-11-30 2007-05-31 Transave, Inc. Safe and effective methods of administering therapeutic agents
HUE029994T2 (en) 2005-12-08 2017-04-28 Insmed Inc Lipid-based compositions of antiinfectives for treating pulmonary infections
AU2008224929A1 (en) * 2007-03-14 2008-09-18 Mayo Foundation For Medical Education And Research Treating skin cancer
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9611313B2 (en) * 2007-06-26 2017-04-04 University Of Miami Antibody-endostatin fusion protein and its variants
RU2365370C1 (ru) * 2008-04-29 2009-08-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН Способ лечения рака легкого
RU2367436C1 (ru) * 2008-05-26 2009-09-20 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН Способ лечения рака легкого
WO2010003057A2 (en) 2008-07-03 2010-01-07 Mayo Foundation For Medical Education And Research Treating cancer
RU2388503C1 (ru) * 2008-08-14 2010-05-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" Способ лечения рака легкого
RU2402280C2 (ru) * 2008-12-01 2010-10-27 Федеральное государственное учреждение "Российский научно-исследовательский онкологический институт Росмедтехнологий" Способ прогнозирования церебральных метастазов рака легкого
RU2406452C1 (ru) * 2009-06-22 2010-12-20 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" Способ лечения рака легкого
RU2414894C1 (ru) * 2009-06-29 2011-03-27 Учреждение Российской академии медицинских наук Российский онкологический научный центр имени Н.Н. Блохина РАМН Способ лечения рака легкого
WO2011056650A2 (en) 2009-10-27 2011-05-12 Michael Zasloff Methods and compositions for treating and preventing viral infections
WO2011066260A2 (en) * 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols
RU2411018C1 (ru) * 2009-12-22 2011-02-10 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" Способ локальной химиотерапии метастазов в печень
RU2429842C1 (ru) * 2010-06-15 2011-09-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) Способ профилактики послеоперационных осложнений при комбинированном лечении больных немелкоклеточным раком легкого iii стадии
PT2707030T (pt) 2011-05-09 2020-05-22 Mayo Found Medical Education & Res Tratamentos de cancro
HUE039389T2 (hu) * 2012-03-30 2019-01-28 Univ California Az anti-EMP2 terápia csökkenti a rák õssejteket
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
MX369828B (es) 2012-05-21 2019-11-22 Insmed Inc Sistemas para tratar infecciones pulmonares.
CN121606602A (zh) 2012-09-04 2026-03-06 埃莱森制药股份有限公司 用顺铂脂质复合物预防癌症的肺部复发
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
RU2018135921A (ru) 2012-11-29 2019-02-05 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
SMT202000516T1 (it) 2014-05-15 2020-11-10 Insmed Inc Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
US20160250351A1 (en) 2014-06-13 2016-09-01 Mayo Foundation For Medical Education And Research Treating Lymphomas
EP3834889A1 (en) 2014-06-16 2021-06-16 Mayo Foundation for Medical Education and Research Treating myelomas
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
US11305020B2 (en) 2016-03-21 2022-04-19 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CA3035377A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Nanoparticle compositions for targeting t-cell cancers
CN109890419A (zh) 2016-09-01 2019-06-14 梅约医学教育与研究基金会 用于治疗癌症的载体-pd-l1结合剂组合物
EP3509643A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
WO2018048816A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Methods of treating pd-l1 expressing cancer
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
MA50094A (fr) 2017-09-08 2020-07-15 Enterin Inc Méthodes de traitement des troubles du sommeil, des perturbations du sommeil et de symptômes associés à l'aide de compositions d'aminostérol
WO2019089603A1 (en) * 2017-10-31 2019-05-09 Dana-Farber Cancer Institute, Inc. Methods for determining and treating cellular resistance to adp-ribosylating toxin
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
WO2019213398A1 (en) 2018-05-02 2019-11-07 Insmed Incorporated Methods for the manufacture of liposomal drug formulations
CN116407640B (zh) * 2023-03-03 2025-10-31 河南真实生物科技有限公司 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3016390A (en) * 1960-06-30 1962-01-09 Searle & Co N-(substituted alkyl) amino-5alpha-androstan-17beta-ols
US3370070A (en) * 1965-06-16 1968-02-20 Searle & Co [n-alkyl-17-(dialkylaminoalkyl)amino] androst-4-en-3-ones
GB1565351A (en) * 1975-06-02 1980-04-16 Theramex Steroid aminoethers
US4220598A (en) * 1977-11-14 1980-09-02 Abbott Laboratories Method and reagents for measuring the level of conjugated bile acids
US4550163A (en) * 1979-02-05 1985-10-29 Abbott Laboratories Ligand analog-irreversible enzyme inhibitor conjugates
US4372888A (en) * 1980-08-26 1983-02-08 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Nondenaturing zwitterionic detergents
JPS5842878B2 (ja) * 1981-12-02 1983-09-22 名糖産業株式会社 １２−オキソコラン酸トシルヒドラゾン化合物、その製法ならびに利用
DE3366932D1 (en) * 1982-07-29 1986-11-20 Lehner Ag New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
US5001116A (en) * 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4994443A (en) * 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
IT1221734B (it) * 1983-02-24 1990-07-12 Schiena Michele Giuseppe Di Ursodesossicolico solfato acido sale sodico
US4545938A (en) * 1983-11-02 1985-10-08 Beth Israel Medical Center Chemical synthesis
JPS6133121A (ja) * 1984-07-25 1986-02-17 Nissei Marine Kogyo Kk 制癌剤
WO1987002367A2 (en) * 1985-10-18 1987-04-23 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US4771042A (en) * 1985-11-25 1988-09-13 The Upjohn Company Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
JPS62175497A (ja) * 1986-01-28 1987-08-01 Wakunaga Pharmaceut Co Ltd 胆汁酸誘導体およびその製造法
US5075464A (en) * 1987-04-22 1991-12-24 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropylamino)androstene derivatives
SE8702254D0 (sv) * 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
IT1229570B (it) * 1989-04-17 1991-09-04 Giuliani Spa Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
IT1229569B (it) * 1989-04-17 1991-09-04 Giuliani Spa Derivati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
JPH07116215B2 (ja) * 1989-04-19 1995-12-13 エスエス製薬株式会社 新規なステロイド化合物
PT93847A (pt) * 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
US4966897A (en) * 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US5004737A (en) * 1989-09-22 1991-04-02 Pacific Chemical Co., Ltd. Quaternary ammonium-substituted sterol derivatives
EP0466315A3 (en) * 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
WO1991019731A1 (en) * 1990-06-11 1991-12-26 The Upjohn Company Steroids which inhibit angiogenesis
NZ240846A (en) * 1990-12-06 1994-04-27 Hoechst Ag Dimeric bile acid derivatives; preparatory processes and pharmaceutical compositions
US5192756A (en) * 1992-03-18 1993-03-09 The Children's Hospital Of Pennsylvania Aminosterol antibiotic
WO1993025197A1 (en) * 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
WO1994019366A1 (en) * 1993-02-26 1994-09-01 Magainin Pharmaceuticals Inc. Chemical synthesis of squalamine
DE69412596T2 (de) * 1993-03-10 1999-03-04 Magainin Pharmaceuticals Inc., Plymouth Meeting, Pa. Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel
JPH09509959A (ja) * 1994-03-10 1997-10-07 マガイニン ファーマシューティカルズ インク． ステロイド誘導体、それらを含む薬剤組成物、及びそれらの薬剤学的用途
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
ATE259375T1 (de) * 1995-06-07 2004-02-15 Genaera Corp Aminosterinverbindungen als inhibitoren der natrium/proton-pump, pharmazeutische methoden und präparaten davon

Also Published As

Publication number Publication date
CA2252584A1 (en) 1997-11-06
DE69722793T2 (de) 2004-05-19
AU2744197A (en) 1997-11-19
ATE242635T1 (de) 2003-06-15
US6147060A (en) 2000-11-14
DK0910382T3 (da) 2003-10-06
PT910382E (pt) 2003-10-31
CA2252584C (en) 2008-06-10
EP0910382B1 (en) 2003-06-11
EP0910382A1 (en) 1999-04-28
DE69722793D1 (de) 2003-07-17
WO1997040835A1 (en) 1997-11-06
AU735884B2 (en) 2001-07-19
JP2000510460A (ja) 2000-08-15

Similar Documents

Publication Publication Date Title
ES2201296T3 (es) Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores.
US6596712B2 (en) Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
ES2435452T3 (es) Métodos y composiciones para tratar un cáncer recurrente
CN101511372B (zh) 包含h2-阻断剂、至少一种抗炎剂和细胞毒性剂的抗癌药物组合物
ES2394264T3 (es) Meta-arsenito de sodio para uso en el tratamiento de enfermedades neoplásicas metastásicas
BR112019026486A2 (pt) tinostamustina para uso no tratamento de câncer de ovário
CA3067058A1 (en) Compounds for treating tnbc
BR112013014642A2 (pt) produto farmacêutico, kit, uso, produtos, métodos e usos inovadores
KR102569052B1 (ko) 암의 치료를 위한 약제학적 조합물
EP1272211B1 (en) Methods and compositions for treating neoplasms
ES2280972T3 (es) Preparaciones farmaceuticas combinadas que contienen glutaminasa y antraciclinas o compuestos de platino antineoplasicos para la terapia del cancer.
Goel et al. Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole.
JP2004510824A (ja) ガンの治療
ES2965807T3 (es) Combinación de temozolomida y un conjugado de PAR-1 para tratar el glioblastoma
ES2396468T3 (es) Composiciones para uso en el tratamiento del síndrome mielodisplástico
Los et al. Anti-tumor effect of cisplatin, carboplatin, mitoxantrone, and doxorubicin on peritoneal tumor growth after intraperitoneal and intravenous chemotherapy: a comparative study
AU757649B2 (en) Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
Welander et al. Combined interferon alf a and doxorubicin in the treatment of advanced cervical cancer
US20250268892A1 (en) Treatment of cancer using aripiprazole and anticancer agent
JP2002524481A5 (2)
Noguès et al. Sequential or simultaneous chemo-radiotherapy in operable breast cancer. A French multicentric phase III study—State of inclusions
PT1773451E (pt) Uso de 7-t-butoxiiminometilcamptotecina para o tratamento de neoplasias uterinas
BR112018011045B1 (pt) Oligonucleotídeo anti-sentido (aso), uso do mesmo na fabricação de um medicamento para o tratamento de câncer e composição farmacêutica